Our grouping. This page groups the registry's lead sponsor names by company — our grouping, not the registry's. It can be wrong or incomplete: an acquired company whose name never mentions its owner may be missing. Use “Something wrong?” under any name below to correct it.
Tell us about a missing company
Serum Institute of India Pvt. Ltd. clinical trials
Also known as SII.
Part of Cyrus Poonawalla Group.
The registry lists 34 studies whose lead sponsor is Serum Institute of India Pvt. Ltd. or one of 3 companies grouped under it. 7 are recruiting or about to start. Per ClinicalTrials.gov, last updated Oct 22, 2026.
Keep track of what changes. Save the Serum Institute of India Pvt. Ltd. studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesRegistry sponsor names on this page
Each name exactly as ClinicalTrials.gov lists it, and how it relates to Serum Institute of India Pvt. Ltd..
- Serum Institute of India Pvt. Ltd.26 studiesSame company
Something wrong?
- Vakzine Projekt Management GmbH4 studies →Acquired
Something wrong?
- Serum Life Science Europe GmbH3 studies →Acquired
Something wrong?
- Bilthoven Biologicals1 study →Acquired — became part of Serum Institute of India Pvt. Ltd., 2012 · source ↗
Something wrong?
Studies
Recruiting first, then most recently updated. Showing 34 of 34.
- Clinical Trial to Assess the Safety, Tolerability, Reactogenicity, and Immunogenicity of a 10 Valent Human Papillomavirus Virus (10vHPV) VaccineNot yet recruitingNCT07888686Phase 1/2
- Safety and Immunogenicity of a Combined Diphtheria, Tetanus, Whole Cell Pertussis, Hepatitis B, Recombinant Poliomyelitis and Haemophilus Influenzae Type b (Hib) Vaccine (SIIPL DTwP-HepB-rPV-Hib)Not yet recruitingNCT07855172Phase 1/2
- Safety and Immunogenicity of a Recombinant Poliomyelitis Vaccine (rPV) in Comparison With IPOL Vaccine in Healthy AdultsRecruitingNCT07688369Phase 1
- Safety and Efficacy of wSp Vaccine in Young ChildrenRecruitingNCT07216430Phase 2
Sponsor listed in the registry: Serum Life Science Europe GmbH · Serum Life Science Europe GmbH — acquired company within the Serum Institute of India Pvt. Ltd. group
- Evaluation of the Antibody Persistence Beyond Five Years After Immunization With MenFiveTM (NmCV-5), a Pentavalent Meningococcal ACYWX Conjugate VaccineRecruitingNCT07379151
- An Observational Study to Assess Effectiveness and Safety of The R21/Matrix-M Malaria VaccineRecruitingNCT07009847
- A Study of SII Yellow Fever Vaccine to Compare Safety and Immunogenicity With STAMARIL® In Healthy InfantsRecruitingNCT05447377Phase 3
- Pfs230D1 + R21 in Matrix-M1 in African School Children and AdultsActive, not recruitingNCT07147400Phase 2
- Clinical Study to Assess the Immunogenicity and Safety of Hexavalent Vaccine Containing Reduced Dose IPVCompletedNCT06413121Phase 3
- Clinical Study to Evaluate SIIPL qHPV Vaccine (CERVAVAC®) in Women Living With HIV Aged 15-25 YearsActive, not recruitingNCT06281119Phase 3
- Study to Assess VPM1002 in Reducing Healthcare Professionals' Absenteeism in COVID-19 PandemicCompletedNCT04387409Phase 3
Sponsor listed in the registry: Serum Life Science Europe GmbH · Serum Life Science Europe GmbH — acquired company within the Serum Institute of India Pvt. Ltd. group
- Dose-Escalating Study of Pfs230D1 in Combination With R21 in Matrix-M in African AdultsCompletedNCT06507605Phase 1
- Safety Study of a Single Dose of Pneumococcal Whole-Cell Vaccine in Healthy AdultsCompletedNCT07059182Phase 1
Sponsor listed in the registry: Serum Life Science Europe GmbH · Serum Life Science Europe GmbH — acquired company within the Serum Institute of India Pvt. Ltd. group
- Clinical Study of Meningococcal ACYWX Conjugate Vaccine, in 12-16 Month OldsCompletedNCT03295318Phase 2
- Study to Check the Efficacy and Safety of Recombinant BCG Vaccine in Prevention of TB RecurrenceCompletedNCT03152903Phase 2/3
- A Study of SII Yellow Fever Vaccine to Compare Safety and Immunogenicity With STAMARILCompletedNCT05421611Phase 3
- Evaluation of Efficacy and Safety of VPM1002 in Comparison to BCG in Prevention of Tb Infection in InfantsCompletedNCT04351685Phase 3
- A Phase 1 Safety Study of Dengusiil in Healthy AdultsCompletedNCT04035278Phase 1
- Evaluation of Safety and Immunogenicity of Inactivated Adjuvanted Polio Vaccine in Comparison With Licensed Inactivated Poliovirus VaccineCompletedNCT05163561Phase 3
- Study to Assess VPM1002 in Reducing Hospital Admissions and/or Severe Respiratory Infectious Diseases in Elderly in COVID-19 PandemicCompletedNCT04435379Phase 3
Sponsor listed in the registry: Vakzine Projekt Management GmbH · Vakzine Projekt Management GmbH — acquired company within the Serum Institute of India Pvt. Ltd. group
- Study to Evaluate the Lot to Lot Consistency of SIIPL Meningococcal ACYWX Conjugate Vaccine and to Compare Its Safety and Immunogenicity With That of Licensed Meningococcal ACWY Vaccine Menactra® in Healthy Individuals 18-85 Years of AgeCompletedNCT04358731Phase 2/3
- Study to Assess Immunegnicity & Safety of Pentavalent Meningococcal Vaccine (NmCV-5)CompletedNCT03964012Phase 3
- Safety Study of Dengushield in Healthy AdultsCompletedNCT03883620Phase 1
- A Clinical Study Comparing Safety and Immunogenicity of bOPV of Bilthoven BiologicalsCompletedNCT02766816Phase 3
Sponsor listed in the registry: Bilthoven Biologicals · First submitted after Bilthoven Biologicals became part of Serum Institute of India Pvt. Ltd.
- Study Comparing DTP-HB-Hib by Disposable-Syringe Jet Injector To Vaccination By Needle And Syringe In InfantsTerminatedNCT02409095Phase 4
- Phase III Study on Rotavirus Vaccine to Evaluate Lot-to-lot Consistency and Interference With Routine UIP ImmunizationCompletedNCT02584816Phase 3
- Study on Liquid Bovine Rotavirus Pentavalent Vaccine (LBRV-PV) to Evaluate Lot-to-Lot Consistency and to Compare Non-Inferiority With ROTASIIL (Lyophilized BRV-PV) in Healthy Infants in IndiaCompletedNCT03474055Phase 2/3
- A Clinical Trial to Study the Effect and Safety of Rotavirus Vaccine Against Severe Rotavirus Gastroenteritis in Healthy Indian InfantsCompletedNCT02133690Phase 3
- Study to Evaluate the Safety and Immunogenicity of VPM1002 in Comparison With BCG in HIV-exposed/-Unexposed Newborn Infants in South AfricaCompletedNCT02391415Phase 2
- A Clinical Trial to Assess the Safety of a Measles Vaccine (Dry Powder) Administered by Two Different DevicesCompletedNCT01557699Phase 1
- Safety & Immunogenicity of MMR Vaccine by DSJI to That by Needle-Syringe in 15-18 Months Old ChildrenCompletedNCT02253407Phase 4
- Study to Evaluate Safety and Immunogenicity of VPM1002 in Comparison With BCG in Newborn Infants in South AfricaCompletedNCT01479972Phase 2
Sponsor listed in the registry: Vakzine Projekt Management GmbH · Vakzine Projekt Management GmbH — acquired company within the Serum Institute of India Pvt. Ltd. group
- Dose-Escalation Study on Safety and Immunogenicity of VPM1002 in Comparison to BCG in Healthy Volunteers in South AfricaCompletedNCT01113281Phase 1
Sponsor listed in the registry: Vakzine Projekt Management GmbH · Vakzine Projekt Management GmbH — acquired company within the Serum Institute of India Pvt. Ltd. group
- Dose-Escalation Study on Safety and Immunogenicity of VPM1002 in Comparison With BCG in Healthy Male VolunteersCompletedNCT00749034Phase 1
Sponsor listed in the registry: Vakzine Projekt Management GmbH · Vakzine Projekt Management GmbH — acquired company within the Serum Institute of India Pvt. Ltd. group